Since the discovery of the Wnt gene over 30 years ago as the Int1 proto-oncogene involved in the pathology of Mouse Mammary Tumor Virus (MMTV), Wnt expression and signal transduction have been identified as critical components in regulating embryogenesis, cell proliferation, and bone, glucose, and lipid metabolism. Perturbations in Wnt expression, surface receptors, signaling partners (including β-catenin and GSK-3β), and the battery of Wnt-regulated genes (collectively the canonical Wnt pathway) are known to manifest in a variety of clinically relevant disease states, including cancer, osteoporosis, cardiovascular disease, diabetes, and neurodegeneration.
The concept of turning Wnt signaling down or up, like the dial of a thermostat, to compensate for signaling anomalies is an attractive approach for development of therapeutics. The design and implementation of such therapeutics must be carefully rationalized to identify drugs and regimens that deliver the desired activation or inhibition of Wnt signaling without triggering undesirable side-effects associated with tuning the pathway past a point of normal physiology.
Development of Wnt pathway modulating drugs requires the ability to rapidly screen the effect of novel or repurposed compounds and biological therapeutics on the expression of Wnt-regulated genes, and confirmation of such effects by related changes in key signaling components. Together, the LEADING LIGHT™ Wnt Reporter Assay, LEADING LIGHT™ Sclerostin-LRP Screening System and SCREEN-WELL® Wnt Pathway Library facilitate high-throughput analysis of Wnt-related signaling.
Download our application notes:
The LEADING LIGHT™ Wnt Reporter Assay Starter Kit is a high-sensitivity, luciferase-based assay for the analysis of canonical Wnt signaling. The assay uses a 3T3 mouse fibroblast cell line modified with a luciferase reporter gene under the control of Wnt-responsive promoters (TCF/LEF). The chemiluminescent readout is amenable to both 96-well and 384-well plate formats, facilitating high-throughput analysis of Wnt pathway activators and inhibitors.
Enzo Life Sciences continues to expand its portfolio of Wnt Pathway assays with the NEW LEADING LIGHT™ Sclerostin-LRP Screening System. This simple, rapid biochemical binding assay format does not require cell lines or transfection reagents, making it a convenient platform for initial screening of inhibitors of the Wnt antagonist Sclerostin.
The SCREEN-WELL® Wnt Pathway Library offers a convenient solution for benchmarking compounds against a collection of 71 known Wnt modulators. The library is available in 100uL and 500uL formats (dissolved in DMSO) for use as a companion to the LEADING LIGHT™ Wnt Reporter Assay, or individually as a general screening tool for chemical genomics or Wnt assay.
Obtain fully quantitative data with immunometric detection of β-Catenin, total and phosphorylated GSK-3β, and DKK-1 in human, mouse and rat samples.
Enzo offers a wide selection of high-quality reagents for analysis of Wnt related signal transduction, including purified proteins and thoroughly validated monoclonal and polyclonal antibodies.
